Charles River Labs makes succession plans, restructures

July 1, 2009 by MassDevice staff

Wilmington contract research provider announces plan to ease the succession from retiring RMS president Real Renaud to David Molho and restructures its preclinical services division.

Charles River Laboratories International Inc. is making a raft of changes to its two main divisions, research models and services and preclinical services, and to its sales force.

The Wilmington contract research provider said RMS president Real Renaud will retire by the end of 2010 after 45 years with the firm. He'll be replaced by Davide Molho, who'll be promoted from his job running the company's European RMS operation.

The changes to Charles River Labs' PCS business, aimed at streamlining its operations, will see its senior management taking on new responsibilities.

Senior vice president Brian Bathgate will add oversight of global laboratory sciences operations to his duties running CRL's global biopharm arm; fellow SVP Christopher Perkin will oversee site operations in North America and China. Vice president Stephen Durham will run the global toxicology and pathology operations and VP Joseph Siglin will run the company's global Lean Six Sigma program.

And CRL is refining its sales approach, focusing on "value-based solutions by customer segment" rather than its former concentration on selling products and services.

That means establishing a three-pronged sales organization aimed at global biopharmaceutical companies, small and mid-sized pharma and biotech firms and the academic/government market.